Cargando…

Correction: Complement inhibitor CSMD1 acts as tumor suppressor in human breast cancer

Detalles Bibliográficos
Autores principales:	Escudero-Esparza, Astrid, Bartoschek, Michael, Gialeli, Chrysostomi, Okroj, Marcin, Owen, Sioned, Jirström, Karin, Orimo, Akira, Jiang, Wen G., Pietras, Kristian, Blom, Anna M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2023
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10197954/ https://www.ncbi.nlm.nih.gov/pubmed/37204255 http://dx.doi.org/10.18632/oncotarget.28426

Ejemplares similares

Complement inhibitor CSMD1 acts as tumor suppressor in human breast cancer
por: Escudero-Esparza, Astrid, et al.
Publicado: (2016)

The human complement inhibitor Sushi Domain-Containing Protein 4 (SUSD4) expression in tumor cells and infiltrating T cells is associated with better prognosis of breast cancer patients
por: Englund, Emelie, et al.
Publicado: (2015)

Complement inhibitor CSMD1 modulates epidermal growth factor receptor oncogenic signaling and sensitizes breast cancer cells to chemotherapy
por: Gialeli, Chrysostomi, et al.
Publicado: (2021)

Correction: Complement inhibitor CSMD1 modulates epidermal growth factor receptor oncogenic signaling and sensitizes breast cancer cells to chemotherapy
por: Gialeli, Chrysostomi, et al.
Publicado: (2023)

Expression of Cartilage Oligomeric Matrix Protein in colorectal cancer is an adverse prognostic factor and correlates negatively with infiltrating immune cells and PD-L1 expression
por: Blom, Anna M., et al.
Publicado: (2023)

Expression of cartilage oligomeric matrix protein in periampullary adenocarcinoma is associated with pancreatobiliary-type morphology, higher levels of fibrosis and immune cell exclusion
por: Papadakos, Konstantinos S., et al.
Publicado: (2022)

Rare mutations in the complement regulatory gene CSMD1 are associated with male and female infertility
por: Lee, Arthur S., et al.
Publicado: (2019)

Extracellular matrix: paving the way to the newest trends in atherosclerosis
por: Gialeli, Chrysostomi, et al.
Publicado: (2021)

Editorial: Complement and Immunotherapeutics
por: Okrój, Marcin, et al.
Publicado: (2021)

Functional Analyses of Complement Convertases Using C3 and C5-Depleted Sera
por: Okroj, Marcin, et al.
Publicado: (2012)

Analysis of complement biomarkers in systemic sclerosis indicates a distinct pattern in scleroderma renal crisis
por: Okrój, Marcin, et al.
Publicado: (2016)

Complement Activation as a Helping Hand for Inflammophilic Pathogens and Cancer
por: Okrój, Marcin, et al.
Publicado: (2019)

Editorial: Expert opinions and perspectives in complement: 2022
por: Okrój, Marcin, et al.
Publicado: (2023)

Loss of CSMD1 disrupts mammary epithelial morphogenesis
por: Kamal, M, et al.
Publicado: (2010)

The Role of Csmd1 during Mammary Gland Development
por: Burgess, Samuel J., et al.
Publicado: (2021)

Deregulation of complement components C4A and CSMD1 peripheral expression in first-episode psychosis and links to cognitive ability
por: Hatzimanolis, Alex, et al.
Publicado: (2022)

The complement system is activated in synovial fluid from subjects with knee injury and from patients with osteoarthritis
por: Struglics, André, et al.
Publicado: (2016)

Mutations resulting in the formation of hyperactive complement convertases support cytocidal effect of anti-CD20 immunotherapeutics
por: Felberg, Anna, et al.
Publicado: (2019)

Neuropsychological Deficits in Mice Depleted of the Schizophrenia Susceptibility Gene CSMD1
por: Steen, Vidar M., et al.
Publicado: (2013)

Assessment of Behaviors Modeling Aspects of Schizophrenia in Csmd1 Mutant Mice
por: Distler, Margaret G., et al.
Publicado: (2012)

Altered expression of the CSMD1 gene in the peripheral blood of schizophrenia patients
por: Liu, Yansong, et al.
Publicado: (2019)

Monitoring of the Complement System Status in Patients With B-Cell Malignancies Treated With Rituximab
por: Felberg, Anna, et al.
Publicado: (2020)

Epigenetic inactivation and aberrant transcription of CSMD1 in squamous cell carcinoma cell lines
por: Richter, Toni M, et al.
Publicado: (2005)

Genetic Variants in CSMD1 Gene Are Associated with Cognitive Performance in Normal Elderly Population
por: Stepanov, Vadim, et al.
Publicado: (2017)

CSMD3 is Associated with Tumor Mutation Burden and Immune Infiltration in Ovarian Cancer Patients
por: Lu, Nan, et al.
Publicado: (2021)

Association of CSMD1 with Tumor Mutation Burden and Other Clinical Outcomes in Gastric Cancer
por: Wang, Xuning, et al.
Publicado: (2021)

The Diverse Role of CUB and Sushi Multiple Domains 1 (CSMD1) in Human Diseases
por: Ermis Akyuz, Esra, et al.
Publicado: (2022)

Overactivity of Alternative Pathway Convertases in Patients With Complement-Mediated Renal Diseases
por: Michels, Marloes A. H. M., et al.
Publicado: (2018)

Csmd2 Is a Synaptic Transmembrane Protein that Interacts with PSD-95 and Is Required for Neuronal Maturation
por: Gutierrez, Mark A., et al.
Publicado: (2019)

Whole-exome sequencing associates novel CSMD1 gene mutations with familial Parkinson disease
por: Ruiz-Martínez, Javier, et al.
Publicado: (2017)

LncRNA CSMD1-1 promotes the progression of Hepatocellular Carcinoma by activating MYC signaling
por: Liu, Ji, et al.
Publicado: (2020)

Integrated pan-cancer analysis of CSMD2 as a potential prognostic, diagnostic, and immune biomarker
por: Zhang, Huiyun, et al.
Publicado: (2022)

Complement C4d-specific antibodies for the diagnosis of lung cancer
por: Ajona, Daniel, et al.
Publicado: (2017)

Testing the Activity of Complement Convertases in Serum/Plasma for Diagnosis of C4NeF-Mediated C3 Glomerulonephritis
por: Blom, Anna M., et al.
Publicado: (2016)

Complement inhibitor factor H expressed by breast cancer cells differentiates CD14(+) human monocytes into immunosuppressive macrophages
por: Smolag, Karolina I., et al.
Publicado: (2020)

No association between the rs10503253 polymorphism in the CSMD1 gene and schizophrenia in a Han Chinese population
por: Liu, Yansong, et al.
Publicado: (2016)

Sustained response to pembrolizumab without prior chemotherapy in high-grade serous ovarian carcinoma with CSMD3 mutation
por: Terzic, Julie, et al.
Publicado: (2020)

Combined identification of ARID1A, CSMD1, and SENP3 as effective prognostic biomarkers for hepatocellular carcinoma
por: Zhao, Yuanyuan, et al.
Publicado: (2021)

CSMD1 Mutations Are Associated with Increased Mutational Burden, Favorable Prognosis, and Anti-Tumor Immunity in Gastric Cancer
por: Huang, Taobi, et al.
Publicado: (2021)

In Silico Designed Gain-of-Function Variants of Complement C2 Support Cytocidal Activity of Anticancer Monoclonal Antibodies
por: Urban, Aleksandra, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_pf1rb6d46kgdpiiisceodbqogt